October 1, 2025

Cardiac and Obstetric Outcomes Associated With Mitral Valve Prolapse

Mitral valve prolapse (MVP) is the most common valvular heart disease in women of reproductive age. Whether MVP increases the likelihood of adverse outcomes in pregnancy is unknown. The study objective was to examine the cardiac and obstetric outcomes associated with MVP in pregnant women. This retrospective cohort study, using the Healthcare Cost and Utilization Project National Readmission Sample database between 2010 and 2017, identified all pregnant women with MVP using the International Classification of Disease, Ninth and Tenth Revisions codes. The maternal cardiac and obstetric outcomes in pregnant women diagnosed with MVP were compared with women without MVP using multivariable logistic and Cox proportional hazard regression models adjusted for baseline demographic characteristics. There were 23,000 pregnancy admissions with MVP with an overall incidence of 16.9 cases per 10,000 pregnancy admissions. Pregnant women with MVP were more likely to die during pregnancy (adjusted hazard ratio 5.13, 95% confidence interval [CI] 1.09 to 24.16), develop cardiac arrest (adjusted odds ratio [aOR] 4.44, 95% CI 1.04 to 18.89), arrhythmia (aOR 10.96, 95% CI 9.17 to 13.12), stroke (aOR 6.90, 95% CI 1.26 to 37.58), heart failure (aOR 5.81, 95% CI 3.84 to 8.79), or suffer a coronary artery dissection (aOR 25.22, 95% CI 3.42 to 186.07) compared with women without MVP. Pregnancies with MVP were also associated with increased risks of preterm delivery (aOR 1.21, 95%CI 1.02 to 1.44) and preeclampsia/hemolysis, elevated liver enzymes, and low platelets syndrome (aOR 1.22, 95% CI 1.05 to 1.41). In conclusion, MVP in pregnancy is associated with adverse maternal cardiac outcomes and higher obstetric risks.

Read more

Register for the Cardiac Conditions in Obstetric Care Fall Learning Session

Our fall meeting will be held virtually on October 22 from 1200 – 1400 and will feature -

1200 – 1300, Dr. Cat Albright, Maternal Fetal Medicine from University of Washington will present on Cardiac Disease in Pregnancy.



Catherine Albright, MD MS is a board-certified Maternal-Fetal Medicine specialist. Her primary focus is on high risk maternal conditions such as maternal cardiac disease and hypertension. Dr. Albright is the director of the Obstetric Hypertension Program and co-director of the Cardio-Obstetrics Program at UW Medical Center - Montlake.

Dr. Albright strives to help women through their complex and often emotional pregnancies by ensuring they understand each step of the process and by actively engaging them, their partners and their families at every visit.

Dr. Albright earned her MD from Columbia then did her OB/Gyn residency, MFM fellowship, and MS in Clinical and Translational research from Brown University. Her clinical and research interests include medical complications, critical care, cardiac disease including adult congenital heart disease, and sepsis in pregnancy, as well as cost-effectiveness analysis.

1300 – 1400, presentation of various QI projects from your colleagues throughout the state

-with discussion throughout

We look forward to meeting with you.

Keith M Cochran

qiadvisor@pqcnc.org

984-974-7871

'Unoffice' hours - click here to schedule a Zoom meeting